Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis
Silvio Danese, Markus F. Neurath, Adam Kopoń, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 18, Iss. 11, pp. 2526-2534.e9
Open Access | Times Cited: 72

Showing 26-50 of 72 citing articles:

Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compounds
Pardis Mansouri, Pegah Mansouri, Sohrab Najafipour, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians’ Perspective
Carsten Schmidt, Philip C. Grunert, Andreas Stallmach
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 23
Emerging therapeutic options in inflammatory bowel disease
Jesús K. Yamamoto‐Furusho, Norma N. Parra-Holguín
World Journal of Gastroenterology (2021) Vol. 27, Iss. 48, pp. 8242-8261
Open Access | Times Cited: 23
Intermittent treatment with Apremilast, a phosphodiesterase-4 inhibitor, ameliorates Alzheimer's-like pathology and symptoms through multiple targeting actions in aged T2D rats
Adel A. Gomaa, Hanan S.M. Farghaly, Asmaa M. Ahmed, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109927-109927
Closed Access | Times Cited: 9
Dual biological therapy and small molecules in pediatric inflammatory bowel disease
Francesca Penagini, Luisa Lonoce, Luisa Abbattista, et al.
Pharmacological Research (2023) Vol. 196, pp. 106935-106935
Open Access | Times Cited: 9
Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?
Fabian Proft, Tuğba İzci Duran, Kamran Ghoreschi, et al.
Autoimmunity Reviews (2024), pp. 103638-103638
Open Access | Times Cited: 3
New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?
Ferdinando D’Amico, Laurent Peyrin‐Biroulet, Silvio Danese, et al.
Current Opinion in Pharmacology (2020) Vol. 55, pp. 141-150
Closed Access | Times Cited: 20
Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases
Andrea Picchianti Diamanti, Francesca Romana Spinelli, Maria Manuela Rosado, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2638-2638
Open Access | Times Cited: 17
Precision therapy for ulcerative colitis: insights from mitochondrial dysfunction interacting with the immune microenvironment
Yifan Zhang, Meng-ying Fan, Qi-rui Bai, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Network Meta‐Analysis: Histologic and Histo‐Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis
María Manuela Estevinho, Bernardo Sousa‐Pinto, Paula Moreira, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 10, pp. 1276-1292
Closed Access | Times Cited: 2
Psoriasis management tree based on comorbidity
S. Abu Amara, Anusha Pasumarthi, Neil Parikh, et al.
International Journal of Dermatology (2024)
Closed Access | Times Cited: 2
Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK
Nurulamin M Noor, Ailsa Hart, Peter M. Irving, et al.
Journal of Crohn s and Colitis (2020) Vol. 14, Iss. 12, pp. 1769-1776
Open Access | Times Cited: 17
Phosphodiesterase 4 inhibitors in diabetic nephropathy
Mitsugi Ookawara, Yasunori Nio
Cellular Signalling (2021) Vol. 90, pp. 110185-110185
Closed Access | Times Cited: 15
Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases
Haobai Liu, Quan Wang, Yue Huang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 242, pp. 114631-114631
Closed Access | Times Cited: 11
IBD therapeutics: what is in the pipeline?
Alexandros Toskas, Ayesha Akbar
Frontline Gastroenterology (2022) Vol. 13, Iss. e1, pp. e35-e43
Open Access | Times Cited: 10
Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies
Paul Bahnam, Jurij Hanžel, Christopher Ma, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 3, pp. 404-417
Closed Access | Times Cited: 9
Review article: Externally derived control arms—An opportunity for clinical trials in inflammatory bowel disease?
Sailish Honap, Laurent Peyrin‐Biroulet
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 7, pp. 659-667
Open Access | Times Cited: 5
Managing Ulcerative Colitis and Crohn’s Disease: Should the Target Be Endoscopy, Histology, or Both?
Fernando Magro, María Manuela Estevinho, André Valois
Journal of the Canadian Association of Gastroenterology (2023) Vol. 7, Iss. 1, pp. 46-58
Open Access | Times Cited: 5
Current Status of Medical Therapy for Inflammatory Bowel Disease: The Wealth of Medications
Neil Nadpara, Zachary Wilmer Reichenbach, Adam C. Ehrlich, et al.
Digestive Diseases and Sciences (2020) Vol. 65, Iss. 10, pp. 2769-2779
Closed Access | Times Cited: 13
Managing psoriatic arthritis in different clinical scenarios
Rubén Queiró, Marta Loredo, Ignacio Braña, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 12, pp. 1469-1484
Closed Access | Times Cited: 4
Exosomes derived from cancer cells relieve inflammatory bowel disease in mice
Shuyi Zhang, Guangyao Li, Kewen Qian, et al.
Journal of drug targeting (2024) Vol. 32, Iss. 9, pp. 1073-1085
Closed Access | Times Cited: 1
Anti-Inflammatory Effects of miR-369-3p via PDE4B in Intestinal Inflammatory Response
Viviana Scalavino, Emanuele Piccinno, Nicoletta Labarile, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8463-8463
Open Access | Times Cited: 1
TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases
Irene Marafini, Edoardo Troncone, Silvia Salvatori, et al.
Pharmacological Research (2020) Vol. 155, pp. 104757-104757
Closed Access | Times Cited: 10
Gene expression profiling in white blood cells reveals new insights into the molecular mechanisms of thalidomide in children with inflammatory bowel disease
Letizia Pugnetti, Debora Curci, Carlotta Bidoli, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 164, pp. 114927-114927
Open Access | Times Cited: 3
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis
Radhika Nittala, Ayaskanta Singh
Clinical Gastroenterology and Hepatology (2020) Vol. 18, Iss. 13, pp. 3057-3057
Open Access | Times Cited: 6

Scroll to top